Mechanisms of Αiibβ3 Biogenesis in the Megakaryocyte: A Proteomics Approach

Amanda Chen,Haiqiang Yu,Haiteng Deng,W. Beau
DOI: https://doi.org/10.5772/35777
2012-01-01
Abstract:Platelets play a central role in hemostasis and thrombosis, initiating clot formation in response to vessel wall damage. Platelet aggregates are formed at sites of injury by the binding and crosslinking of the integrin IIb3 to fibrinogen, von Willebrand factor and other soluble ligands. Platelets also form pathological thrombi, and the resulting arterial occlusion can lead to myocardial infarction or stroke. Inhibition of IIb3 binding can decrease the formation of pathologic thrombi, and IIb3 has become an important pharmacological target. Anti-IIb3 therapies have been highly successful in preventing death following myocardial infarction and percutaneous arterial stent placement.(Topol, Lincoff et al. 2002; De Luca, Ucci et al. 2009) However, attempts to design novel, orally available anti-IIb3 agents have been hampered by what appears to be paradoxical activation of IIb3 by the drug, in some cases leading to an increased risk of mortality in patients who received the drug.(Quinn, Plow et al. 2002)
What problem does this paper attempt to address?